Metastatic Bladder Cancer (DBCOND0054408)

Identifiers

Synonyms

Bladder Cancer, Metastatic

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Docetaxel	A taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer.	Apoptosis regulator Bcl-2target Tubulin beta-1 chaintarget Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 10transporter Cytochrome P450 1B1enzyme Microtubule-associated protein 2target Microtubule-associated protein 4target Microtubule-associated protein tautarget Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 7transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 2transporter Multidrug resistance-associated protein 1transporter Nuclear receptor subfamily 1 group I member 2target
Paclitaxel	A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer.	Apoptosis regulator Bcl-2target Tubulin beta-1 chaintarget Cytochrome P450 2C8enzyme Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Bile salt export pumptransporter ATP-dependent translocase ABCB1transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 10transporter Aromataseenzyme Cytochrome P450 1B1enzyme Solute carrier organic anion transporter family member 1B3transporter Nuclear receptor subfamily 1 group I member 2target Microtubule-associated protein 4target Microtubule-associated protein 2target Microtubule-associated protein tautarget ATP-binding cassette sub-family C member 2transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02989584	A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer	Atezolizumab Cisplatin Gemcitabine	treatment	1 / 2	active_not_recruiting
NCT06138561	Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments	No drug interventions	Not Available	Not Available	recruiting
NCT02028442	Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients	Enadenotucirev	treatment	1 / 2	completed
NCT05259319	Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)	Atezolizumab Tiragolumab	treatment	1	recruiting
NCT03498196	A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer	Avelumab	treatment	1 / 2	terminated
NCT04887831	Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab	Avelumab Carboplatin Cisplatin Gemcitabine Trilaciclib	treatment	2	terminated
NCT06129084	A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing	No drug interventions	Not Available	Not Available	recruiting
NCT04200963	A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma	Nivolumab	treatment	1	completed
NCT01454089	A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer	Apatorsen Carboplatin Cisplatin Gemcitabine	treatment	2	completed
NCT02030067	Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies	Fluorocyclopentenylcytosine	treatment	1 / 2	completed
NCT03430895	Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract	Durvalumab Tremelimumab	treatment	2	completed
NCT01814150	The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel	No drug interventions	Not Available	Not Available	unknown_status
NCT04138628	Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy	Atezolizumab	diagnostic	2	recruiting